Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00068068
Status:
COMPLETED
Last Update Posted:
2006-09-19
First Post:
2003-09-04
Brief Title:
Photodynamic Therapy With Talaporfin Sodium LS11 in Treating Patients With Refractory Colorectal Liver Metastases
Sponsor:
Light Sciences LLC
Organization:
Light Sciences LLC
Study Overview
Official Title:
Safety and Efficacy of Treating Refractory Cancers With the Litx System Phase II Safety and Efficacy Study in Patients With Liver Metastases From Colorectal Cancer That Have Failed Chemotherapy
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer Litx is a next-generation photodynamic therapy platform in which the drug talaporfin sodium LS11 is activated by light from the light-emitting diode LED-based light infusion device inserted directly into the tumor through the skin prior to treatment
Detailed Description:
Patients that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT or ultrasound guided percutaneous placement of a single two three or four light infusion devices depending on their tumor characteristics No more than 4 light sources will be used at a single treatment The light infusion devices may be used in a single lesion or in multiple lesions
Following radiographic confirmation of light infusion device placement patients will receive an intravenous dose of LS11 at 40 mgm² One hour following completion of LS11 administration delivery of 200 Jcm light energy will begin The light infusion device will then be manually removed and the patients will be observed for acute complication of light infusion device removal Precautions for protection from external light exposure should be instituted beginning with the LS11 administration and be maintained as defined throughout the study period On day 305 the patient will undergo clinical assessment and the tumor mass will be imaged using contrast enhanced spiral CT for determination of volume and radius of the tumor size as well as tumor necrosis The patient may then receive 5-FU andor leucovorin either irinotecan or oxaliplatin standard chemotherapy at day 30 visit All patients with or without chemotherapy at day 30 will undergo final clinical assessment and final tumor imaging evaluation using contrast CT at day 605 of Litx treatment
Following radiographic confirmation of light infusion device placement patients will receive an intravenous dose of LS11 at 40 mgm² One hour following completion of LS11 administration delivery of 200 Jcm light energy will begin The light infusion device will then be manually removed and the patients will be observed for acute complication of light infusion device removal Precautions for protection from external light exposure should be instituted beginning with the LS11 administration and be maintained as defined throughout the study period On day 305 the patient will undergo clinical assessment and the tumor mass will be imaged using contrast enhanced spiral CT for determination of volume and radius of the tumor size as well as tumor necrosis The patient may then receive 5-FU andor leucovorin either irinotecan or oxaliplatin standard chemotherapy at day 30 visit All patients with or without chemotherapy at day 30 will undergo final clinical assessment and final tumor imaging evaluation using contrast CT at day 605 of Litx treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None